TY - JOUR
T1 - Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma
AU - Berdeja, Jesüs G.
AU - Jones, Richard J.
AU - Zahurak, Marianna L.
AU - Piantadosi, Steven
AU - Abrams, Ross A.
AU - Borowitz, Michael J.
AU - Vogelsang, Georgia B.
AU - Noga, Stephen J.
AU - Ambinder, Richard F.
AU - Flinn, Ian W.
PY - 2001
Y1 - 2001
N2 - Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and <2 prior treatments; rates of EFS were 0% (95% CI, 0%-0%) and 79% (95% CI, 47%-93%), respectively. Conclusion: These data show that, with T-cell depletion, the TRM and relapse rates are modest for patients with sensitive disease and <2 prior treatment courses. Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease.
AB - Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and <2 prior treatments; rates of EFS were 0% (95% CI, 0%-0%) and 79% (95% CI, 47%-93%), respectively. Conclusion: These data show that, with T-cell depletion, the TRM and relapse rates are modest for patients with sensitive disease and <2 prior treatment courses. Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease.
KW - AlloBMT
KW - Chronic lymphocytic leukemia
KW - Event-free survival
KW - Follicular lymphoma
KW - Graft-versus-lymphoma effect
KW - Mantle cell lymphoma
KW - Transplantation-related morbidity
UR - http://www.scopus.com/inward/record.url?scp=0035204544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035204544&partnerID=8YFLogxK
U2 - 10.1016/S1083-8791(01)70016-X
DO - 10.1016/S1083-8791(01)70016-X
M3 - Article
C2 - 11760088
AN - SCOPUS:0035204544
SN - 1083-8791
VL - 7
SP - 561
EP - 567
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 10
ER -